The American Diabetes Association’s own consensus definition of type 2 diabetes remission — HbA1c < 6.5% for at least 3 months, off all glucose-lowering medication — just turned five years old, and a growing body of 2026 evidence shows that the vast majority of patients on mainstream diabetes drugs never get close to meeting it. The ADA’s consensus statement, published in 2021 with the Endocrine Society, EASD, and Diabetes UK, deliberately uses the word “remission” — not “reversal,” not “cure,” not “resolution” — because the ADA believes those words overstate what the evidence supports. For the 38 million Americans living with Type 2 diabetes, this is being framed as the establishment finally acknowledging the possibility of getting off medication. It is — for a small fraction of patients, under very specific conditions. It is not, and cannot be, a reversal.

What Just Happened

The ADA’s 2021 consensus statement on diabetes remission — jointly issued with the Endocrine Society, EASD, and Diabetes UK — remains the operative international standard in 2026, as detailed in ADA Meeting News coverage and the Diabetes on the Net summary.

The headline points from the ADA consensus, Endocrine Society and ADA Meeting News:

• The remission definition: HbA1c < 6.5% (48 mmol/mol) for at least 3 months, with no usual glucose-lowering pharmacotherapy during that period.
• Why the ADA chose “remission,” not “reversal”: The consensus panel deliberately rejected “reversal,” “cure,” and “resolution” — terms that imply a permanent end to the disease — because hyperglycemia can recur even after years of normal glucose.
• Alternative criteria when HbA1c is unreliable: When HbA1c is not a reliable marker (e.g., certain hemoglobinopathies), the consensus allows fasting plasma glucose < 126 mg/dL or CGM-derived estimated HbA1c (eA1c) / glucose management indicator (GMI) < 6.5% as alternate criteria, per the Diabetes on the Net summary.
• Ongoing follow-up requirement: After remission is documented, the consensus requires testing at least yearly to confirm continued remission and screen for complications — because the disease can come back.
• The 2026 reality: Five years after the consensus, mainstream Type 2 diabetes management (metformin, GLP-1s, insulin, SGLT2 inhibitors) still treats the disease as chronic and progressive. The remission criteria exist — but the drugs most patients are prescribed don’t target remission as an outcome.

The Question Nobody’s Asking

Here’s what every headline about the ADA’s remission definition is leaving out: the ADA wrote the bar lower than reversal, and most patients still never clear it.

The ADA’s consensus defines “remission” — not “reversal” — as HbA1c < 6.5% for at least 3 months off all medication. That’s a deliberately conservative bar. “Remission” means the disease is not currently active, but it acknowledges the disease could come back. “Reversal” would mean the disease is functionally gone. The ADA chose the weaker word on purpose because the evidence supports remission, not reversal, for patients treated with standard pharmacotherapy.

But even the remission bar is rarely cleared. Five years after the consensus, the vast majority of patients on
metformin, GLP-1s, insulin, or SGLT2 inhibitors never achieve HbA1c < 6.5% off all medication for 3+ months. The drugs lower A1c while you take them. When you stop, the A1c climbs back. The underlying insulin resistance never gets addressed. The medication overrides the symptom while the disease keeps running the show.

That’s not a flaw in the consensus. It’s a careful, honest definition. But “low bar most patients never clear” and
“reversal of Type 2 diabetes” are two completely different games.

So the real question for the millions of Americans whose endocrinologists follow the ADA’s consensus isn’t “is
remission possible?” It’s “why am I still diabetic in the first place, and what’s actually required to reverse it?”

What Reversal Actually Looks Like

At Diabetes Reversal Group, we measure reversal by a single, unblinking standard: A1c 6.4% or lower — off
every diabetes medication — sustained. Not “controlled.” Not “managed.” Reversed.

Our patients hit reversal in an average of 4.5 months — the time to get the attached results, within the 5-month average from the independent study. The mechanism isn’t a molecule. It’s a system: a patented nutrition protocol (240 recipes, 7-day meal plans, telemedicine delivery, mobile app coaching) that reverses the underlying insulin resistance at the root. The world’s only patented protocol for Type 2 diabetes reversal (U.S. patent granted September 2020), validated by an independent study (2013–2021) showing an average post-program A1c of 6.04%.

The Bottom Line

The ADA’s own remission definition is a careful, honest bar — and most patients on standard drugs never clear
it. A system that reverses the disease is a different game entirely — one the ADA’s own language distinguishes
from remission on purpose.

If you’re on metformin, a GLP-1, or insulin, and you’ve been told you’ll be on it for life, you owe it to yourself to
look at what’s actually possible. Watch our free webinar.

No pitch. Just the science, the data, and how to know if you’re a candidate.

By: Dr. Jeffrey Hockings / Co-Founder/CEO / Diabetes Reversal Group / Kristine Burke, MD / Chief Medical
Officer / Diabetes Reversal Group.

The only patented system in the world proven to reverse Type 2 diabetes